Black Rock Inc. Landos Biopharma, Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.26 - $0.55 $2,453 - $5,190	9,437 Added 38.71%	33,815 $10,000
Q4 2022 Feb 13, 2023	SELL	$0.22 - $0.51 $59,951 - $138,978	-272,507 Reduced 91.79%	24,378 $12,000
Q3 2022 Nov 14, 2022	SELL	$0.67 - $1.26 $11,963 - $22,498	-17,856 Reduced 5.67%	296,885 $193,000
Q2 2022 Aug 12, 2022	SELL	$0.6 - $1.5 $123,340 - $308,350	-205,567 Reduced 39.51%	314,741 $229,000
Q1 2022 May 12, 2022	BUY	$1.44 - $5.22 $71,827 - $260,373	49,880 Added 10.6%	520,308 $767,000
Q4 2021 Feb 10, 2022	BUY	$4.7 - $15.0 $1.11 Million - $3.55 Million	236,812 Added 101.37%	470,428 $2.26 Million
Q3 2021 Nov 09, 2021	SELL	$9.77 - $15.77 $590,371 - $952,933	-60,427 Reduced 20.55%	233,616 $3.41 Million
Q2 2021 Aug 11, 2021	BUY	$9.26 - $12.53 $2.72 Million - $3.68 Million	294,043 New	294,043 $3.4 Million

Ticker LABP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,254,900
Description
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of u...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.